Altreno (tretinoin) / Bausch Health 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   33 News 
  • ||||||||||  Winlevi (clascoterone cream 1%) / Cassiopea
    Journal:  Drugs for acne. (Pubmed Central) -  Jan 31, 2024   
    N=37 --> 25 No abstract available
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) -  Jul 13, 2023   
    P4,  N=37, Completed, 
    No abstract available Active, not recruiting --> Completed | N=60 --> 37 | Trial completion date: Mar 2023 --> Aug 2022 | Trial primary completion date: Feb 2023 --> Aug 2022
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Enrollment closed, Trial completion date, Trial primary completion date:  Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) -  Dec 16, 2022   
    P4,  N=60, Active, not recruiting, 
    Active, not recruiting --> Completed | N=60 --> 37 | Trial completion date: Mar 2023 --> Aug 2022 | Trial primary completion date: Feb 2023 --> Aug 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
  • ||||||||||  Winlevi (clascoterone cream 1%) / Cassiopea
    Journal:  Clascoterone cream (Winlevi) for acne. (Pubmed Central) -  Feb 8, 2022   
    doi:10.36849/JDD.6658. No abstract available
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Trial primary completion date:  Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) -  Aug 18, 2021   
    P4,  N=60, Recruiting, 
    doi:10.36849/JDD.6182. Trial primary completion date: Aug 2021 --> Aug 2022
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Clinical, Retrospective data, Journal:  Tolerability of tretinoin lotion 0.05% for moderate to severe acne vulgaris: a post hoc analysis in a black population. (Pubmed Central) -  Jul 15, 2021   
    However, the potential for retinoids to induce an irritant contact dermatitis, which could lead to PIH, is a concern. A lotion formulation of tretinoin was developed to provide an important alternative option to treat acne in black patients who may be sensitive to the irritant effects of other tretinoin formulations or where PIH is a concern.
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    [VIRTUAL] Impact of Body Mass Index (BMI) on Efficacy of Three Topical Acne Treatments in Patients with Moderate-to-Severe Acne () -  Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_218;    
    For vehicle-treated participants, formulation type may have affected responses; greater lesion reductions were observed with polymeric-emulsion lotion vehicles versus gel vehicle and improvements with both polymeric-emulsion vehicles were greatest in obese participants. In summary, BMI did not affect treatment outcomes with 3 topical acne medications (C/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, tazarotene 0.045% lotion); results are notable given the limited clinical data on BMI and potential impacts on the efficacy of acne treatments.
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Enrollment closed, Trial primary completion date:  Altreno for Chest Rejuvenation (clinicaltrials.gov) -  Apr 1, 2021   
    P4,  N=40, Active, not recruiting, 
    In summary, BMI did not affect treatment outcomes with 3 topical acne medications (C/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, tazarotene 0.045% lotion); results are notable given the limited clinical data on BMI and potential impacts on the efficacy of acne treatments. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2021 --> Jul 2021
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Enrollment open, Trial initiation date, Trial primary completion date:  Profiling the Skin Microbiome in Response to Altreno in Acne Patients (clinicaltrials.gov) -  Feb 24, 2021   
    P4,  N=60, Recruiting, 
    It also underlines the under-reporting of these ADRs and the importance of strengthening hearing monitoring in children during and long after drug exposure. Not yet recruiting --> Recruiting | Initiation date: Oct 2020 --> Mar 2021 | Trial primary completion date: May 2021 --> Aug 2021
  • ||||||||||  Winlevi (clascoterone cream 1%) / Cassiopea, Differin (adapalene) / Galderma
    Journal:  Drugs for acne. (Pubmed Central) -  Jan 23, 2021   
    Tretinoin 0.05% lotion did not interfere with facial makeup application or wearability and was well tolerated. No abstract available
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Enrollment open, Trial completion date, Trial primary completion date:  Altreno for Chest Rejuvenation (clinicaltrials.gov) -  Jan 6, 2021   
    P4,  N=40, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    New P4 trial:  Altreno for Chest Rejuvenation (clinicaltrials.gov) -  Sep 19, 2019   
    P4,  N=40, Not yet recruiting, 
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Phase classification:  Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris (clinicaltrials.gov) -  Jan 10, 2018   
    P3,  N=820, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021 Phase classification: P1 --> P3
  • ||||||||||  Altreno (tretinoin) / Bausch Health
    Trial completion, Trial primary completion date:  Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris (clinicaltrials.gov) -  Apr 27, 2017   
    P1,  N=820, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Feb 2017 Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Feb 2017